A Study of NWY001 in Subjects With Advanced Solid Tumors
ConditionAdvanced Solid Tumor
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-75
SponsorChipscreen Biosciences, Ltd.
About this trial
This is a Phase 1, single-arm, open-label, dose-escalation study in patients with advanced solid tumors including 2 parts:
Part 1: Dose-Escalation Part Part 2: Dose-Expansion Part
Eligibility criteria
Qualifiers
Willingness to sign a written informed consent document
Participant with advanced solid malignant tumor that has relapsed from or is refractory to standard therapy or for which no standard therapy exists
18~75 years of age at the time of screening
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
Disqualifiers
previous history of non-aggressive malignancies, such as cervical carcinoma in situ, melanoma in situ, or ductal carcinoma in situ of the breast that remains in complete remission for years after curative treatment
malignancies with negligible risk of metastasis or death (such as adequately treated basal or squamous cell skin cancer and focal prostate cancer)
Trial design
Treatments tested in this trial
- NWY001
- NWY001
Treatment groups
196 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov